Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EphB1-Mediated Transient Blood-Brain Barrier Opening Facilitates a Ferritin-Based Nanotherapeutic for Alzheimer's Disease.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Non-telomeric function deficiency of TERT enhances pressure overload-induced mouse cardiac remodeling by activation of CNBP-mediated THBS3/ITGB1 pathway.

Acta pharmacologica Sinica·2026

Same author

The Landscape of Ferritin Nanocages for Neurodegenerative Diseases Treatment.

International journal of nanomedicine·2026

Same author

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection.

Alimentary pharmacology & therapeutics·2026

Same author

Impact of hospital volume on outcomes of esophagectomy for esophageal cancer: analysis of a prospective multicenter database.

Surgical endoscopy·2025

Same author

RGD-functionalized ultrasmall ceria nanozymes ameliorate sepsis via dual modulation of inflammatory cascades and gut microbiota dysbiosis.

International journal of pharmaceutics·2025

Search research articles

Related Experiment Video

Updated: Apr 10, 2026

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Published on: October 8, 2012

Current Drug Targets for Thymic Neoplasms.

Xiao-Ling Xu, Wei-Min Mao¹

¹Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, 310022, Zhejiang Province, China. maowm1318@163.com.

Current Cancer Drug Targets

|June 17, 2015

Summary

Targeted therapy offers a promising alternative for thymic malignancies resistant to chemotherapy. This review explores potential drug targets and clinical trial outcomes for thymoma treatment.

More Related Videos

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Apr 10, 2026

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Published on: October 8, 2012

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Oncology
Medical Research

Background:

Thymic neoplasms are rare malignant tumors, with surgical resection as the primary treatment.
Chemotherapy is vital for unresectable or metastatic thymic tumors, but response rates are limited to approximately two-thirds.
Chemotherapy-resistant cases necessitate alternative treatment strategies.

Purpose of the Study:

To review current potential drug targets in thymic malignancy development.
To discuss drugs used in targeted therapy for thymoma and their clinical trial results.
To provide an overview of patient selection for targeted therapy and its efficacy in refractory or recurrent thymic tumors.

Main Methods:

Literature review of existing case reports and clinical trials.
Analysis of genes implicated in thymic tumorigenesis and metastasis.
Evaluation of targeted therapy agents and their efficacy.

Main Results:

Several targeted therapy inhibitors, including sorafenib and sunitinib, have shown effectiveness in thymoma treatment.
Identification of numerous genes as potential therapeutic targets in thymic malignancies.
Evidence suggests targeted therapy can benefit patients with refractory or recurrent thymic tumors.

Conclusions:

Targeted therapy presents a viable and beneficial alternative for patients with thymic malignancies resistant to conventional chemotherapy.
Further research into specific patient screening and novel drug targets is crucial for optimizing thymoma treatment outcomes.